Spyre Therapeutics, Inc. Common Stock (SYRE) Stock Price

SYREStock

$107.36+513.64%52W

Market Cap$9.47B

P/E—

PEG Ratio—

Div yield—

Beta3.08

SYRE Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)180.15%

Price vs S&P 500 (4W)3.64%

VGM Score84.09

Book Value / Share (Quarterly)$12.50

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-2.37

Price vs S&P 500 (YTD)213.59%

Net Profit Margin (TTM)-22158.54%

EPS (TTM)$-2.32

10-Day Avg Trading Volume0.83M

EPS Excl Extra (TTM)$-2.32

EPS (Annual)$-2.42

ROI (Annual)-21.70%

Net Profit Margin (5Y Avg)-8769.93%

Cash / Share (Quarterly)$13.01

ROA (Last FY)-19.95%

EBITD / Share (TTM)$-2.69

ROE (5Y Avg)-86.62%

Operating Margin (TTM)-17559.35%

Cash Flow / Share (Annual)$-2.16

P/B Ratio8.15x

P/B Ratio (Quarterly)7.00x

Net Income / Employee (Annual)$-1,521,600

Net Interest Coverage (TTM)-6.19x

ROA (TTM)-22.23%

EPS Incl Extra (Annual)$-2.42

Current Ratio (Annual)13.25x

Quick Ratio (Quarterly)18.09x

3-Month Avg Trading Volume1.22M

52-Week Price Return513.64%

Revenue / Employee (TTM)$0

P/S Ratio (Annual)10129.04x

Asset Turnover (Annual)0.00x

52-Week High$110.17

Operating Margin (5Y Avg)-6607.37%

EPS Excl Extra (Annual)$-2.42

26-Week Price Return191.39%

Quick Ratio (Annual)12.89x

13-Week Price Return43.50%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)18.53x

Enterprise Value$8.81B

Asset Turnover (TTM)0.01x

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-38241.08%

Cash / Share (Annual)$9.68

3-Month Return Std Dev65.12%

Net Income / Employee (TTM)$-1,754,100

ROE (Last FY)-21.70%

Net Interest Coverage (Annual)-2.14x

EPS Basic Excl Extra (Annual)$-2.42

Receivables Turnover (TTM)2.51x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.32

Receivables Turnover (Annual)2.51x

ROI (TTM)-24.32%

P/S Ratio (TTM)7296.20x

Pretax Margin (5Y Avg)-8771.48%

Revenue / Share (Annual)$0.00

Price vs S&P 500 (52W)495.33%

Year-to-Date Return225.55%

5-Day Price Return-1.09%

EPS Normalized (Annual)$-2.42

ROA (5Y Avg)-66.20%

Net Profit Margin (Annual)-38238.15%

Month-to-Date Return8.46%

EBITD / Share (Annual)$-3.27

Operating Margin (Annual)-27347.97%

ROI (5Y Avg)-86.54%

EPS Basic Excl Extra (TTM)$-2.32

P/B Ratio (Annual)3.55x

Pretax Margin (TTM)-22174.80%

Book Value / Share (Annual)$9.15

Price vs S&P 500 (13W)40.71%

Beta3.08x

Revenue / Share (TTM)$0.00

ROE (TTM)-24.32%

52-Week Low$14.51

mGradeA

vgmGradeA

SYRE Earnings Surprise History

Q2 25-0.49est. -0.71

Q3 25-0.15est. -0.74

Q4 25-0.74est. -0.80

Q1 26-0.74est. -0.65

Q2 26-0.36est. -0.75

SYRE Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.48

4.39

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$67.01

About Spyre Therapeutics, Inc. Common Stock

Spyre Therapeutics is a clinical-stage biotechnology company developing long-acting antibodies for inflammatory bowel disease and rheumatic diseases. The company's pipeline features extended half-life antibodies targeting α4β7, TL1A, and IL-23, evaluated as monotherapies and pair-wise combinations to improve treatment outcomes and reduce dosing frequency.